Literature DB >> 1660414

Elevated glucocorticoid receptor concentrations before and after glucocorticoid therapy in peripheral mononuclear leukocytes of patients with atopic dermatitis.

M Rupprecht1, R Rupprecht, J Kornhuber, N Wodarz, H U Koch, P Riederer, O P Hornstein.   

Abstract

The number and affinity of glucocorticoid binding sites in peripheral mononuclear leukocytes of patients with atopic dermatitis (AD) and healthy controls were determined under baseline conditions and after a defined oral glucocorticoid treatment. Patients with AD (n = 15) exhibited significantly more glucocorticoid receptors (GR) per cell than the control group (n = 22), while the GR affinity did not differ. Methylprednisolone treatment resulted in a significant reduction of the GR sites per cell in the steroid-treated control group (n = 10) in contrast to the patients. The dissociation constant was not affected by methylprednisolone treatment in either group. In view of the therapeutic efficiency of glucocorticoids in AD and findings of abnormal cAMP and cAMP-phosphodiesterase activity, the elevated GR concentrations in AD lend support to the hypothesis of a compensatory GR upregulation due to an insufficient action of endogenous cortisol or to altered cAMP-induced GR expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1660414     DOI: 10.1159/000247646

Source DB:  PubMed          Journal:  Dermatologica        ISSN: 0011-9075


  2 in total

1.  In vivo and in vitro effects of glucocorticoids on lectin-induced blastogenesis in atopic dermatitis.

Authors:  M Rupprecht; R Rupprecht; N Wodarz; H U Braner; J Kornhuber; H U Koch; P Riederer; O P Hornstein
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

Review 2.  Psychoneuroimmunology of psychological stress and atopic dermatitis: pathophysiologic and therapeutic updates.

Authors:  Andrea L Suárez; Jamison D Feramisco; John Koo; Martin Steinhoff
Journal:  Acta Derm Venereol       Date:  2012-01       Impact factor: 4.437

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.